Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-Label, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer

NCT06011304 is registered in ClinicalTrials.gov with HTA Co., Ltd. as lead sponsor.

NCT NCT06011304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06011304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-Label, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
Lead sponsor
HTA Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 20, 2023
Completion date
April 16, 2026
Enrollment
287 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer